Overview

A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Status:
Terminated
Trial end date:
2016-10-14
Target enrollment:
Participant gender:
Summary
A phase 1 study of DCR-PH1 in patients with primary hyperoxaluria type 1 (PH1) to determine the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics (PD) effects of DCR-PH1 administered via-intravenous infusion (IV)
Phase:
Phase 1
Details
Lead Sponsor:
Dicerna Pharmaceuticals, Inc.